{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:47:37Z","timestamp":1788238057337,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071412"],"award-info":[{"award-number":["82071412"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH337, ZR2021QH120"],"award-info":[{"award-number":["ZR2021MH337, ZR2021QH120"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2019GSF108064"],"award-info":[{"award-number":["2019GSF108064"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Autoimmune nodopathy with anti-contactin-1 (CNTN1) responds well to rituximab instead of traditional therapies. Although a low-dose rituximab regimen was administered to patients with other autoimmune diseases, such as myasthenia gravis and neuromyelitis optica spectrum disorders, and satisfactory outcomes were obtained, this low-dose rituximab regimen has not been trialed in anti-CNTN1-positive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anti\u2013CNTN1 nodopathy patients were enrolled in this prospective, open-label, self-controlled pilot study. A cell-based assay was used to detect anti-CNTN1 antibodies and their subclasses in both serum and cerebrospinal fluid. Clinical features were evaluated at baseline, 2 days, 14 days, and 6 months after single low-dose rituximab treatment (600 mg). The titers of the subclasses of anti-CNTN1 antibody and peripheral B cells were also evaluated at baseline, 2 days, and 6 months after the rituximab regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two patients with anti\u2013CNTN1 antibodies were enrolled. Both patients had neurological symptoms including muscle weakness, tremor, sensory ataxia, numbness and mild nephrotic symptoms. In the field of neurological symptoms, sensory ataxia markedly improved, and the titer of anti-CNTN1 antibody as well as CD19+ B cells decreased only two days following low-dose rituximab treatment. Other neurological symptoms improved within two weeks of rituximab treatment. At the 6-month follow-up, all neurological symptoms steadily improved with steroid reduction, and both the anti-CNTN1 antibody titer and CD19+ B cells steadily decreased. No adverse events were observed after this single low-dose rituximab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We confirmed the clinical efficacy of low-dose rituximab by B cell depletion in autoimmune nodopathy with anti-CNTN1 antibody. This rapid and long-lasting response suggests that low-dose rituximab is a promising option for anti-CNTN1 nodopathy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.939062","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T16:48:32Z","timestamp":1658854112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Miura","year":"2015","journal-title":"Brain"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006625","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in CIDP","volume":"91","author":"Koike","year":"2018","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10041-z","article-title":"Antibodies against the node of ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera","volume":"267","author":"Delmont","year":"2020","journal-title":"J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S358851","article-title":"Efficacy and safety of low-dose rituximab in anti-MuSK myasthenia gravis patients: A retrospective study","volume":"18","author":"Meng","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309916","article-title":"Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies","volume":"86","author":"Doppler","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000771","article-title":"Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates","volume":"7","author":"Dubey","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.02.063","article-title":"Isaacs syndrome with CASPR2 antibody: A series of three cases","volume":"41","author":"Song","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory b cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and b-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/acn3.51550","article-title":"Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in han Chinese","volume":"9","author":"Wang","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x.","article-title":"European Federation of neurological Societies\/Peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society - first revision","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.3.615.","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2016-315480","article-title":"Nodes, paranodes and neuropathies","volume":"89","author":"Fehmi","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283412fd4","article-title":"What is IgG4? a review of the biology of a unique immunoglobulin subtype","volume":"23","author":"Nirula","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04264-1","article-title":"Aggressive anti-LGI1 encephalitis defeated by one cycle of intravenous rituximab-a case report","volume":"41","author":"Markovic","year":"2020","journal-title":"Neurol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jamaneurol.2014.463","article-title":"Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy","volume":"71","author":"Irani","year":"2014","journal-title":"JAMA Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12164","article-title":"Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory morvan syndrome associated with anti-CASPR2 antibodies","volume":"20","author":"Ong","year":"2013","journal-title":"Eur J Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1886630","article-title":"B cell targeted therapy for immunoglobulin G4-related disease","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Immunol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.02.049","article-title":"Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease","volume":"16","author":"Majumder","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-mediated neurologic autoimmunities: Understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-b cell therapies","volume":"9","author":"Dalakas","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948454","article-title":"Divergent chemokine receptor expression and the consequence for human IgG4 b cell responses","volume":"50","author":"Unger","year":"2020","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.528489","article-title":"Specific contactin n-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies","volume":"289","author":"Labasque","year":"2014","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"J Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26392","article-title":"\"Neuro-renal syndrome\" related to anti-contactin-1 antibodies","volume":"59","author":"Taieb","year":"2019","journal-title":"Muscle Nerve"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B37","first-page":"199","article-title":"Rapid recovery of chronic inflammatory demyelinating polyneuropathy induced by steroid pulse therapy\u2013changes in nerve conduction","volume":"33","author":"Hishida","year":"1993","journal-title":"Rinsho Shinkeigaku"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00997","article-title":"Chronic inflammatory demyelinating polyneuropathy with concurrent membranous nephropathy: An anti-paranode and podocyte protein antibody study and literature survey","volume":"9","author":"Hashimoto","year":"2018","journal-title":"Front Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785247","article-title":"Anti-neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: A comparative study","volume":"12","author":"Endmayr","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759187","article-title":"Characteristics of anti-Contactin1 antibody-associated autoimmune nodopathies with concomitant membranous nephropathy","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000395","article-title":"Rituximab responsive relapsing-remitting IgG4 anticontactin 1 chronic inflammatory demyelinating polyradiculoneuropathy associated with membranous nephropathy: A case description and brief review","volume":"23","author":"Remiche","year":"2022","journal-title":"J Clin Neuromuscul Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.029","article-title":"Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab","volume":"100","author":"Plaisier","year":"2021","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-642-27843-3_94-1","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw251","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx105","article-title":"Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience","volume":"11","author":"Bagchi","year":"2018","journal-title":"Clin Kidney J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27233","article-title":"Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody","volume":"63","author":"Zhou","year":"2021","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00642","article-title":"Retrospective observation of low-dose rituximab treatment in Chinese patients with neuromyelitis optica spectrum disorders in a real-world setting","volume":"11","author":"Xiao","year":"2020","journal-title":"Front Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"577280","DOI":"10.1016\/j.jneuroim.2020.577280","article-title":"Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155","volume":"345","author":"Jiao","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","author":"Du","year":"2022","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.939062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T16:48:38Z","timestamp":1658854118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.939062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.939062"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.939062","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"939062"}}